Table 4 The direct comparison meta-analysis results of outcomes.

From: Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis

Outcomes

TPO-RA vs PLA

n

N (TPO-RA vs PLA)

Heterogeneity

Model

RR

95%CI

P

Overall platelet response

ELT vs PLA

2

108 vs 51

I2 = 26%, P = 0.24

Fixed

2.64

[1.58, 4.44]

0.0002

ROM vs PLA

3

71 vs 31

I2 = 0%, P = 0.55

Fixed

5.05

[2.21, 11.53]

0.0001

Durable platelet response

ELT vs PLA

2

108 vs 51

I2 = 0%, P = 0.83

Fixed

13.14

[2.67, 64.64]

0.002

ROM vs PLA

1

42 vs 20

NA

NA

5.24

[1.36, 20.13]

0.02

Clinically significant bleeding

ELT vs PLA

2

108 vs 51

I2 = 0%, P = 0.39

Fixed

0.37

[0.15, 0.93]

0.04

ROM vs PLA

2

59 vs 24

I2 = 0%, P = 0.94

Fixed

1.11

[0.78, 1.58]

0.57

All bleeding events

ELT vs PLA

2

108 vs 51

I2 = 63%, P = 0.10

Random

0.50

[0.29, 0.87]

0.01

ROM vs PLA

2

59 vs 24

I2 = 0%, P = 0.42

Fixed

1.22

[0.89, 1.66]

0.21

Rescue treatment

ELT vs PLA

2

108 vs 51

I2 = 69%, P = 0.07

Random

0.46

[0.16, 1.34]

0.15

ROM vs PLA

3

71 vs 31

I2 = 21%, P = 0.28

Fixed

0.70

[0.41, 1.20]

0.19

All adverse events

ELT vs PLA

2

107 vs 50

I2 = 73%, P = 0.06

Random

0.97

[0.72, 1.29]

0.82

ROM vs PLA

2

29 vs 11

I2 = 0%, P = 1.00

Fixed

1.00

[0.69, 1.45]

1.00

Serious adverse events

ELT vs PLA

2

107 vs 50

I2 = 0%, P = 0.63

Fixed

0.70

[0.26, 1.86]

0.48

ROM vs PLA

3

71 vs 30

I2 = 0%, P = 0.41

Fixed

3.28

[0.65, 16.60]

0.15

Headache

ELT vs PLA

2

107 vs 50

I2 = 0%, P = 0.70

Fixed

0.75

[0.41, 1.37]

0.35

ROM vs PLA

3

71 vs 30

I2 = 0%, P = 0.92

Fixed

0.75

[0.46, 1.20]

0.23

Vomiting

ELT vs PLA

2

107 vs 50

I2 = 0%, P = 0.97

Fixed

0.31

[0.12, 0.82]

0.02

ROM vs PLA

3

71 vs 30

I2 = 10%, P = 0.33

Fixed

0.85

[0.38, 1.87]

0.68

Upper respiratory tract infection

ELT vs PLA

2

107 vs 50

I2 = 0%, P = 0.87

Fixed

2.83

[0.88, 9.07]

0.08

ROM vs PLA

2

59 vs 24

I2 = 0%, P = 0.45

Fixed

1.29

[0.59, 2.81]

0.52

Pyrexia

ELT vs PLA

2

107 vs 50

I2 = 0%, P = 0.60

Fixed

1.18

[0.39, 3.53]

0.77

ROM vs PLA

2

59 vs 24

I2 = 0%, P = 0.81

Fixed

2.24

[0.63, 8.02]

0.21

Cough

ELT vs PLA

2

107 vs 50

I2 = 0%, P = 0.73

Fixed

5.24

[0.69, 39.64]

0.11

ROM vs PLA

2

29 vs 11

I2 = 0%, P = 0.73

Fixed

0.36

[0.09, 1.47]

0.15

Epistaxis

ELT vs PLA

1

63 vs 29

NA

NA

0.61

[0.23, 1.61]

0.32

ROM vs PLA

3

71 vs 30

I2 = 0%, P = 0.71

Fixed

0.95

[0.57, 1.59]

0.85

Oropharyngeal pain

ELT vs PLA

1

44 vs 21

NA

NA

2.39

[0.30, 19.16]

0.41

ROM vs PLA

2

59 vs 24

I2 = 0%, P = 0.77

Fixed

4.28

[0.86, 21.26]

0.08

Abdominal pain

ELT vs PLA

2

107 vs 50

I2 = 45%, P = 0.18

Fixed

1.80

[0.46, 7.01]

0.40

ROM vs PLA

1

17 vs 5

NA

NA

0.29

[0.02, 3.91]

0.35

Upper abdominal pain

ELT vs PLA

1

63 vs 29

NA

NA

0.35

[0.08, 1.44]

0.15

ROM vs PLA

1

17 vs 5

NA

NA

2.33

[0.14, 38.97]

0.56

Diarrhoea

ELT vs PLA

1

44 vs 21

NA

NA

3.34

[0.44, 25.43]

0.24

ROM vs PLA

1

42 vs 19

NA

NA

1.51

[0.47, 4.86]

0.49

Nausea

ELT vs PLA

1

44 vs 21

NA

NA

0.48

[0.17, 1.30]

0.15

ROM vs PLA

1

42 vs 19

NA

NA

0.58

[0.25, 1.33]

0.20

Nasopharyngitis

ELT vs PLA

1

63 vs 29

NA

NA

2.53

[0.60, 10.70]

0.21

ROM vs PLA

1

17 vs 5

NA

NA

1.67

[0.09, 30.06]

0.73

  1. n: number of included studies; N: number of patients; ELT: Eltrombopag; ROM: Romiplostim; PLA: Placebo; RR: Risk Ratio; CI: confidence interval; NA: not applicable; Fixed: Fixed-effect model; Random: Random-effect model.
Back to article page